EUVIMEDEUVIMED entdecken
Crossref

Development and Purification of Polyclonal Antibody Against Glargine in Rabbits

Sandeep Chakravarthi Kuppirala, Somasekhar Reddy Kanala

Future Journal of Pharmaceuticals and Health Sciences · 01.07.2026 · 6 (1) · 1-10

DOI: 10.26452/fjphs.v6si1.907 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Journal of Pharmaceuticals and Health Sciences, online erschienen am 01.07.2026. Verfasst von Sandeep Chakravarthi Kuppirala und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunogenicity assessment requires the detection of anti-drug antibodies (ADAs) towards therapeutic insulin analogues like insulin glargine. The absence of well-characterized positive control antibodies is however a significant limitation in developing the immunogenicity assays. Rabbit-derived polyclonal antibodies against insulin glargine were successfully generated and affinity-purified for use as positive control antibodies in bridge ELISA-based immunogenicity assays.Insulin glargine was conjugated to keyhole limpet hemocyanin (KLH) using glutaraldehyde-mediated crosslinking followed by sodium borohydride stabilization. Rabbits were immunized subcutaneously with the conjugate using Freund’s adjuvants according to a scheduled booster regimen. Antibody titers were determined by indirect ELISA using BSA-glargine–coated plates to avoid anti-KLH interference. Serum IgG was purified through Protein A affinity chromatography followed by glargine-conjugated Affi-Gel affinity purification. Purity was evaluated by SDS-PAGE. Five out of six immunized rabbits developed strong immune responses with endpoint titers reaching 1:32,000–1:40,000. One animal showed no significant response. Affinity purification yielded highly enriched IgG with improved specificity and reduced non-specific reactivity. SDS-PAGE confirmed antibody purity, and ELISA demonstrated high sensitivity towards glargine with minimal cross-reactivity. A robust and reproducible strategy was established for generating high-titer, affinity-purified polyclonal antibodies against glargine, suitable for immunoassay development and bioanalytical applications.

Zitieren

APA

Kuppirala, S. C., & Kanala, S. R. (2026). Development and Purification of Polyclonal Antibody Against Glargine in Rabbits. Future Journal of Pharmaceuticals and Health Sciences, 6(1), 1-10. https://doi.org/10.26452/fjphs.v6si1.907

Vancouver

Kuppirala SC, Kanala SR. Development and Purification of Polyclonal Antibody Against Glargine in Rabbits. Future Journal of Pharmaceuticals and Health Sciences. 2026;6(1):1-10. doi:10.26452/fjphs.v6si1.907

BibTeX
@article{Kuppirala2026,
  author = {Kuppirala, Sandeep Chakravarthi and Kanala, Somasekhar Reddy},
  title = {Development and Purification of Polyclonal Antibody Against Glargine in Rabbits},
  journal = {Future Journal of Pharmaceuticals and Health Sciences},
  year = {2026},
  volume = {6},
  number = {1},
  pages = {1--10},
  doi = {10.26452/fjphs.v6si1.907}
}
Kostenlos starten →